Featured Publications
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF. Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening. Cancer Discovery 2013, 3: 52-67. PMID: 23239741, PMCID: PMC3546137, DOI: 10.1158/2159-8290.cd-12-0408.Peer-Reviewed Original ResearchConceptsMutant BRAF melanomaCyclin-dependent kinase inhibitorBRAF melanomaSmall molecule inhibitorsHigh-throughput drug screeningDrug screeningEGF receptorCombination therapyDrug combinationsMelanoma culturesContext of genotypePairwise combinationsResistance phenotypeCombinatorial drug screeningUnique treatment regimensCombination of statinsVivo xenograftsKinase inhibitorsMutant BRAFMutationsEfficacious drug combinationsPartial responseTreatment regimensRAS mutationsBRAF mutations
1996
Heregulin-Induced Growth Factor Receptor Signaling and Breast Carcinogenesis.
Riese D, Stern D. Heregulin-Induced Growth Factor Receptor Signaling and Breast Carcinogenesis. 1996 DOI: 10.21236/ada315700.Peer-Reviewed Original ResearchErbB family receptorsCellular signaling proteinsGrowth factor receptor signalingFamily receptorsBa/F3 cell lineCell linesEGF-like growth factorNeu differentiation factorEpidermal growth factor (EGF) familyGrowth factor familySignaling proteinsFactor familyGrowth factor alphaCellular responsesReceptor phosphorylationReceptor signalingErbB familyDistinct activitiesPairwise combinationsDifferentiation factorEGFBetacellulinHeregulinGrowth factorProtein
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply